Dosing has begun in a Phase III study evaluating the contraceptive efficacy of relugolix combination tablet
News
Gilead’s Trodelvy scores accelerated approval in advanced bladder cancer
US Food and Drug Administration approved antibody drug conjugate based on Phase II trial results
NICE publishes new guidance on chronic pain management
Guidelines recommend exercise programmes and psychological therapies rather than commonly used drugs
UK trial evaluating ‘mix and match’ COVID-19 vaccine regimens expanded
Trial will now include vaccines developed by Moderna and Novavax
Antibiotic Research UK launches small research grants programme
Charity will award grants for research projects into antibiotics and antibiotic resistance
Experts call for advanced radiotherapy funding to address COVID-19 cancer care backlog
Cancer experts urge the government to address funding gaps for high-precision radiotherapy
Inhaled asthma drug accelerates recovery from COVID-19
Self-reported recovery was three days shorter for patients receiving inhaled budesonide
Four medicines accepted for use by NHS Scotland
Newly accepted medicines include treatments for multiple myeloma and severe migraine
Take the next step into CROY 2021
The 2021 Clinical Researcher of the Year – The Americas competition is reaching out to the very best in the industry to take the next step and claim gold.
US approval for first AI device to help detect colon cancer
Device designed to help clinicians detect lesions in the colon during a colonoscopy
C4X Discovery agrees licensing deal with Sanofi
Sanofi could pay up to €414m for C4X Discovery’s oral IL-17A inhibitor programme
Early promise for new immunotherapy combo in brain cancer
Experimental drug plus immunotherapy demonstrated early potential in aggressive brain cancer
Farxiga fails to achieve statistical significance in COVID-19 trial
Diabetes drug was unable to prevent all-cause mortality in Phase III study
EU nod for new formulation of Biogen’s Tysabri
A subcutaneous formulation will now be available to treat relapsing-remitting multiple sclerosis
NICE ‘no’ for Opdivo/Yervoy lung cancer combo
The combination is not considered to be a cost-effective use of NHS resources in this setting
